Quit at longest · smoking cessation in hospitalised patients
Pharmacotherapy plus counselling leads to higher quit at longest compared with no pharmacotherapy or placebo plus counselling (high certainty).
3 findings from 1 review
RR 1.33 [1.05, 1.67]
8 studies · 3838 participants
High
RR 1.11 [0.86, 1.43]
4 studies · 872 participants
Low
RR 1.29 [0.96, 1.75]
4 studies · 829 participants
Moderate
Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy (hypertonic saline) probably leads to lower adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (hypertonic saline) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
Pain ( · people with telangiectasias and reticular veins
1 finding from 1 review
Recurrence · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission or improvement · people with irritable bowel syndrome
It is very uncertain whether biofeedback plus standard therapy changes clinical response (adequate improvement or remission) compared with standard therapy (very low certainty).
1 finding from 1 review
Abdominal pain · people with irritable bowel syndrome
1 finding from 1 review
QoL · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (AE) · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain · people with irritable bowel syndrome
1 finding from 1 review
Clinical remission or improvement · people with irritable bowel syndrome
It is very uncertain whether biofeedback plus standard therapy changes clinical response (adequate improvement or remission) compared with sham biofeedback plus standard therapy (very low certainty).
1 finding from 1 review
QoL · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (AE) · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tiredness · people receiving dialysis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exhaustion · people receiving dialysis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found